Your session is about to expire
← Back to Search
Study Summary
This trial is being conducted to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition has not improved after two cancer treatments, including one with anti-CD20.My lymphoma shows up on scans and has at least one large tumor.My organs are working well.My lymphoma is classified as 'double-hit' or 'triple-hit' DLBCL.My lymphoma shows on scans with specific size tumors or nodes.My cancer has spread to my brain or spinal cord.I am able to get out of my bed or chair and move around.My lymphoma is classified as 'double-hit' or 'triple-hit' DLBCL.I have relapsed or refractory DLBCL or FL with CD20+ B-cells.My organs are working well.
- Group 1: Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)
- Group 2: Main Cohort: Epcoritamab Follicular Lymphoma (FL)
- Group 3: Diversity Enriched Cohort: Epcoritamab DLBCL
- Group 4: Diversity Enriched Cohort: Epcoritamab FL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are enrolled in this research study?
"Affirmative. Records on clinicaltrials.gov attest to the fact that this study, initially posted on August 17th 2022, is currently searching for participants. A total of 80 volunteers must be recruited from 45 different sites."
What is the purpose of this research endeavor?
"The primary metric of success for this trial, assessed over a period stretching up to 3 months, is the proportion of participants experiencing Grade 3 or higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events. Secondary outcomes include median time to onset of CRS at Grade 3 intensity or above, rate of patients receiving interventions post first full dose of epcoritamab and percentage of any adverse events experienced by volunteers."
Has the government greenlighted Epcoritamab for therapeutic implementation?
"Epcoritamab's safety level was rated at 2, as there is limited clinical evidence for its efficacy but extant information regarding its security."
Does this experiment currently have room for more volunteers?
"Affirmative. According to the information on clinicaltrials.gov, this medical trial is actively searching for participants and has been since August 17th 2022 when the study was initially posted with its most recent edit occurring November 21st of that same year."
What is the geographic scope of this research endeavor?
"Currently, this clinical trial is operating from 45 different medical centres. Participants can choose the closest site to them among Oklahoma City, San Antonio and Lebanon or any of the other 42 locations. This way they won't need to travel too far for their appointments."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger